[The effect of Tavan (SP-54) on the coagulation mechanism and fibrinolysis in patients receiving anticoagulant therapy].
D001778:Blood Coagulation Disorders / Q000139:chemically induced*; D001780:Blood Coagulation Tests; D002784:Cholesterol / Q000097:blood; D004357:Drug Synergism; D006493:Heparin / Q000627:therapeutic use*; D006496:Heparinoids / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use*
D006496:Heparinoids; D014859:Warfarin; D006493:Heparin; D002784:Cholesterol
Die effek van Tavan (SP-54) op die stollingsmeganisme en fibrinolise by pasiënte op antistolterapie.